Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis

Background: The aim of this study is to evaluate the pharmacoeconomic profile of adding enzalutamide to first-line treatment for metastatic, hormone-sensitive prostate cancer (mHSPC) from the US and Chinese payers' perspectives. Materials and Methods: A Markov model with three health states: pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Peng-Fei, Xie, Dan, Li, Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902073/
https://www.ncbi.nlm.nih.gov/pubmed/33634066
http://dx.doi.org/10.3389/fpubh.2021.608375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902073/
https://www.ncbi.nlm.nih.gov/pubmed/33634066
http://dx.doi.org/10.3389/fpubh.2021.608375

Ejemplares similares